Media Articles Related to Lexiva (Fosamprenavir)
Tenofovir Reduces HIV Infections in Injection Drug Users
Source: Medscape HIV/AIDS Headlines [2013.06.12]
Preexposure prophylaxis with tenofovir disoproxil fumarate nearly halved (48.9%) HIV infection rates in injection drug users compared with placebo.
Medscape Medical News
Baby "Cured" of HIV Infection
Source: MedicineNet Human Immunodeficiency Virus (HIV, AIDS) Specialty [2013.04.03]
Title: Baby "Cured" of HIV Infection
Category: Doctor's & Expert's views on Symptoms
Created: 4/3/2013 6:12:00 PM
Last Editorial Review: 4/3/2013 6:12:53 PM
Antiretroviral Drug Reduces Risk Of Contracting HIV Among Injection Drug Users
Source: HIV / AIDS News From Medical News Today [2013.06.13]
Researchers have found that people who inject drugs could reduce their risk of HIV infection by nearly half if they take daily tablets of an antiretroviral drug called tenofovir disoproxil fumarate (tenofovir). This was the first trial to evaluate whether preventative treatment with HIV drugs could prevent HIV infection among people who inject drugs. Jonathan Mermin, M.D...
New Method Provides Significant Improvement In The Detection Of HIV Antibodies
Source: HIV / AIDS News From Medical News Today [2013.05.28]
Detection of HIV antibodies is used to diagnose HIV infection and monitor trials of experimental HIV/AIDS vaccines. New, more sensitive detection systems being developed use microspheres to capture HIV antibodies and can measure even small amounts of multiple antibodies at one time...
Published Studies Related to Lexiva (Fosamprenavir)
Similar virologic and immunologic efficacy with fosamprenavir boosted with 100 mg or 200 mg of ritonavir in HIV-infected patients: results of the LESS trial. [2010.09]
PURPOSE: ritonavir (RTV) effectively boosts most protease inhibitors but is associated with significant dose-dependent adverse events (AEs). In an effort to better manage toxicities through a reduced dose of RTV, this study compared fosamprenavir (FPV) boosted with RTV 100 mg (FPV/r100) or with RTV 200 mg (FPV/r200) daily...
Impact of low abundance HIV variants on response to ritonavir-boosted atazanavir or fosamprenavir given once daily with tenofovir/emtricitabine in antiretroviral-naive HIV-infected patients. [2010.04]
Population genotyping (PG) can underestimate resistance if resistance-containing low abundance variants go undetected. PG and clonal analysis (CA) results were compared in virologic failures (VFs) from a 48-week clinical trial that evaluated once-daily fosamprenavir/ritonavir (FPV/r) 1400 mg/100 mg or atazanavir/ritonavir (ATV/r) 300 mg/100 mg, each combined with tenofovir/emtricitabine, in antiretroviral-naive patients.
Steady-state amprenavir and tenofovir pharmacokinetics after coadministration of unboosted or ritonavir-boosted fosamprenavir with tenofovir disoproxil fumarate in healthy volunteers. [2010.03]
Objective An open-label, three-period pharmacokinetic study was conducted to investigate the drug interaction potential between fosamprenavir (FPV) and tenofovir disoproxil fumarate (TDF). Methods Thirty-six healthy subjects received TDF 300 mg once daily (qd) for 7 days (period 1), and then were randomized to 14 days of either FPV 1400 mg twice daily (bid) or FPV/ritonavir (RTV) 700/100 mg bid alone or with TDF (period 2)...
The effect of tenofovir disoproxil fumarate on whole-body insulin sensitivity, lipids and adipokines in healthy volunteers. 
BACKGROUND: Certain antiretrovirals are known to affect lipid and glucose homeostasis. The aim of this study was to assess the effect on insulin sensitivity (determined by peripheral glucose uptake using a hyperinsulinaemic euglycaemic clamp) of tenofovir disoproxil fumarate (TDF) administration compared with placebo for 2 weeks in HIV-1-seronegative healthy male volunteers. Changes in lipids, adiponectin, leptin, plasminogen activator inhibitor 1 (PAI-1) and the adhesion molecules E-selectin and P-selectin were also assessed... CONCLUSIONS: TDF use for 2 weeks does not affect insulin sensitivity, as assessed by the hyperinsulinaemic euglycaemic clamp in HIV-negative male volunteers. TDF use resulted in modest, but statistically significant, reductions in total and LDL cholesterol.
Study of once-daily versus twice-daily fosamprenavir plus ritonavir administered with abacavir/lamivudine once daily in antiretroviral-naive HIV-1-infected adult subjects. [2009.11]
PURPOSE: Fosamprenavir/ritonavir 1400 mg/100 mg once-daily regimen may have a more favourable tolerability and lipid profile than the fosamprenavir/ritonavir twice-daily regimen, while maintaining comparable antiviral efficacy... CONCLUSION: Though the study did not continue to stage 2, fosamprenavir/ritonavir once daily demonstrated noninferior antiviral efficacy to fosamprenavir/ritonavir twice daily.
Clinical Trials Related to Lexiva (Fosamprenavir)
A Study To Assess GW433908 (Fosamprenavir) Containing Regimens In HIV-1 Infected Subjects [Completed]
GW433908 (fosamprenavir; FPV)is a pro-drug of amprenavir (APV) which is more water soluble
and can be formulated into a tablet with a reduced pill burden (four 700mg tablets of FPV
versus sixteen 150mg capsules daily for APV. This study is designed to provide additional
information on long term safety and tolerability of FPV containing regimens for those
subjects who received FPV in previous GlaxoSmithKline studies.
Study Of An Investigational Regimen Including FDA Approved HIV Drugs In HIV-Infected Pediatric Subjects [Recruiting]
This is a 48-week study to evaluate the safety, tolerability, pharmacokinetics, and
antiviral activity of an investigational regimen including FDA approved HIV drugs in
HIV-infected pediatric subjects, ages 4 weeks to < 2 years old.
HCV Evolution in HIV/HCV (Genotype 1) Coinfected Patients Treated With Fosamprenavir [Recruiting]
This study examines the impact of fosamprenavir as part of an ART on virological,
immunological and clinical parameters of genotype 1 HCV infection in HIV co-infected
subjects. Fosamprenavir could have a direct or immune-mediated activity against HCV. If this
is shown to be true, changes in HCV viral load or biological characteristics could be
Boosted Lexiva With Lovaza Adjunctive Therapy in Hypertriglyceridemic, HIV-Infected Subjects [Recruiting]
In subjects on boosted protease inhibitor (PI)-regimens who have elevated triglycerides, a
switch to fosamprenavir/ritonavir once daily followed by the addition of Lovaza will result
in 30% of patients achieving a reduction in fasting triglycerides < 200 mg /dL while
maintaining virologic suppression.
Fosamprenavir Expanded Access [No longer available]
This open-label study will enable HIV-infected adults with limited treatment options to
receive fosamprenavir until commercial supplies are available in Switzerland.
Reports of Suspected Lexiva (Fosamprenavir) Side Effects
Gastrointestinal Haemorrhage (3),
Abortion Spontaneous (2),
Herpes Zoster (2),
Abdominal Discomfort (2),
Angina Pectoris (2),
Maternal Exposure During Pregnancy (2),
Confusional State (1),
Immune Reconstitution Syndrome (1),
Foetal Exposure During Pregnancy (1), more >>